当前位置: 首页 > 详情页

Association of miR-197-5p, a circulating biomarker for heart failure, with myocardial fibrosis and adverse cardiovascular events among patients with stage C or D heart failure

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [a]Department of Cardiology, Beijing AnZhen Hospital, Capital Medical University, Beijing, China [b]Department of Cardiothoracic Surgery, Second Affiliated Hospital of Sun Yat-Sen University, Guang Dong, China [c]Department of Radiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China [d]Department of Cardiovascular Surgery, Beijing AnZhen Hospital, Capital Medical University, Beijing, China
出处:
ISSN:

关键词: Heart failure Magnetic resonance imaging micro-RNA Myocardial fibrosis Prognosis

摘要:
Objective: The aim of this study was to identify heart failure (HF)-specific circulating micro-RNAs (miRNA), and examine whether the selected miRNAs correlate with myocardial fibrosis and are reflective of the incidence of adverse cardiovascular events in patients with stage C or D HF. Methods: Circulating miRNAs which were expressed in end-stage HF patients and matched healthy controls were detected by microarray analysis and validated by quantitative real-time polymerase chain reaction. Multivariate Cox regression analysis was performed to determine whether the selected circulating miRNAs could be prognostic factors in HF patients. Results: In a cohort of 7 healthy controls and 9 patients with stage C or D HF, 7 miRNAs were differentially expressed. These miRNAs were further investigated in a second cohort of 80 patients with stage C or D HF and 30 healthy controls. Only miR-197-5P correlated with fibrosis as seen in cardiac magnetic resonance imaging in patients under the age of 50 years with stage C or D HF (r = 0.42, p = 0.008). Multivariate analyses revealed that miR-197-5P was also a risk factor for composite endpoint events in patients under the age of 50 years with stage C or D HF. Conclusion: miR-197-5P is a circulation miRNA that correlates with MF and adverse cardiac events in HF patients under the age of 50 years. © 2019 © 2019 S. Karger AG, Basel.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类 | 4 区 医学
小类 | 4 区 心脏和心血管系统
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 心脏和心血管系统
JCR分区:
出版当年[2017]版:
Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
最新[2023]版:
Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

影响因子: 最新[2023版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者机构: [a]Department of Cardiology, Beijing AnZhen Hospital, Capital Medical University, Beijing, China
共同第一作者:
通讯作者:
通讯机构: [a]Department of Cardiology, Beijing AnZhen Hospital, Capital Medical University, Beijing, China [*1]Department of Cardiology, Beijing AnZhen Hospital Capital Medical University Beijing 100029 (China)
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院